Drug companies and NICE must put their differences aside and think of the men and families at the centre of all this.
The 59-year-old novelist strips off for our new partnership with McEwan's beer, which will see all profits from their McNificent boxer shorts donated to us. He tells us why the pub is so important to get our message out to his generation, and why he'd like to go for a drink with Renton.
Cabazitaxel chemotherapy has been rejected by the Scottish Medicines Consortium (SMC) for routine use on the NHS in Scotland, it has been announced today.
Thanks to our award-winning campaign and our supporters, Scotland has a detailed analysis of the quality of its cancer services for the first time so we can now start targeting where improvements need to be made.
Making sure that men with prostate cancer receive the best treatment and care across the UK is one of our priorities. Find out about the Scottish Government's new cancer plan and what we think.
Treatment for advanced prostate cancer approved for use in Scotland for men who have not yet had chemotherapy.
Abiraterone and radium-223 will be routinely offered on the NHS in Scotland from today, but the campaign for the rest of the UK continues.
We call for pharmaceutical company and health authority to work together so that ‘decency and common sense can prevail’ as the SMC rejects enzalutamide for men with advanced prostate cancer who haven’t had chemotherapy.
The Scottish Medicines Consortium (SMC) announced yesterday that they would not be making abiraterone available on the Scottish NHS for men with advanced prostate cancer that no longer responds to hormone therapy, and who haven’t had chemotherapy. Read more about the decision and what it means for men.
Scotmid Co-operative and Prostate Cancer UK have raised a record breaking £280,000 - nearly doubling the partnership’s original fundraising target of £150,000.